Caribou Biosciences, Inc. Common Stock
CRBU Real Time Price USDRecent trades of CRBU by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by CRBU's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
Estimated quarterly lobbying spending
CRBU Revenue by Segment or Geography
New patents grants
-
Patent Title: Engineered cascade components and cascade complexes Feb. 18, 2025
-
Patent Title: Modified cascade ribonucleoproteins and uses thereof Mar. 26, 2024
-
Patent Title: Engineered cascade components and cascade complexes Jan. 17, 2023
-
Patent Title: Engineered nucleic acid-targeting nucleic acids Nov. 22, 2022
-
Patent Title: Humanized bcma antibody and bcma-car-t cells Oct. 18, 2022
-
Patent Title: Methods of use of crispr cpf1 hybrid dna/rna polynucleotides Oct. 04, 2022
-
Patent Title: Compositions and methods of nucleic acid-targeting nucleic acids Apr. 26, 2022
-
Patent Title: Humanized bcma antibody and bcma-car-t cells Apr. 12, 2022
-
Patent Title: Crispr hybrid dna/rna polynucleotides and methods of use Feb. 01, 2022
-
Patent Title: Engineered nucleic-acid targeting nucleic acids Jan. 18, 2022
-
Patent Title: Methods for using dna repair for cell engineering Oct. 26, 2021
-
Patent Title: Bcma-car-natural killer (nk) cells and methods related thereto Oct. 12, 2021
-
Patent Title: Compositions and methods of engineered crispr-cas9 systems using split-nexus cas9-associated polynucleotides Sep. 07, 2021
-
Patent Title: Humanized bcma antibody and bcma-car-t cells Jun. 01, 2021
-
Patent Title: Engineered nucleic acid-targeting nucleic acids May. 11, 2021
-
Patent Title: Method of target cleaving using crispr hybrid dna/rna polynucleotides Apr. 27, 2021
-
Patent Title: Modified cascade ribonucleoproteins and uses thereof Mar. 23, 2021
-
Patent Title: Humanized bcma antibody and bcma-car-t cells Feb. 23, 2021
-
Patent Title: Engineered cascade components and cascade complexes Sep. 22, 2020
-
Patent Title: Engineered nucleic-acid targeting nucleic acids Jul. 14, 2020
-
Patent Title: Modified cascade ribonucleoproteins and uses thereof Jul. 14, 2020
-
Patent Title: Engineered nucleic-acid targeting nucleic acids Dec. 10, 2019
-
Patent Title: Engineered cascade components and cascade complexes Oct. 29, 2019
-
Patent Title: Modified cascade ribonucleoproteins and uses thereof Oct. 08, 2019
-
Patent Title: Engineered cascade components and cascade complexes Jun. 25, 2019
-
Patent Title: Engineered cascade components and cascade complexes Mar. 12, 2019
-
Patent Title: Engineered nucleic-acid targeting nucleic acids Feb. 05, 2019
-
Patent Title: Engineered nucleic-acid targeting nucleic acids Nov. 27, 2018
-
Patent Title: Methods of modifying a target nucleic acid with an argonaute Nov. 13, 2018
-
Patent Title: Compositions and methods of nucleic acid-targeting nucleic acids Nov. 13, 2018
-
Patent Title: Engineered nucleic-acid targeting nucleic acids Nov. 13, 2018
-
Patent Title: Engineered nucleic acid-targeting nucleic acids Oct. 16, 2018
-
Patent Title: Engineered nucleic-acid targeting nucleic acids Jul. 17, 2018
-
Patent Title: Methods for increasing cas9-mediated engineering efficiency May. 15, 2018
-
Patent Title: Engineered nucleic acid-targeting nucleic acids May. 15, 2018
-
Patent Title: Compositions and methods of engineered crispr-cas9 systems using split-nexus cas9-associated polynucleotides May. 15, 2018
-
Patent Title: Compositions and methods of engineered crispr-cas9 systems using split-nexus cas9-associated polynucleotides May. 15, 2018
-
Patent Title: Cells comprising engineered nucleic-acid targeting nucleic acids May. 01, 2018
-
Patent Title: Compositions and methods of nucleic acid-targeting nucleic acids Mar. 06, 2018
-
Patent Title: Methods of modifying a target nucleic acid with an argonaute Feb. 27, 2018
-
Patent Title: Modified cascade ribonucleoproteins and uses thereof Feb. 06, 2018
-
Patent Title: Engineered nucleic acid-targeting nucleic acids Nov. 14, 2017
-
Patent Title: Engineered nucleic-acid targeting nucleic acids Nov. 14, 2017
-
Patent Title: Compositions and methods of nucleic acid-targeting nucleic acids Nov. 07, 2017
-
Patent Title: Compositions and methods of nucleic acid-targeting nucleic acids Oct. 31, 2017
-
Patent Title: Engineered nucleic acid-targeting nucleic acids Sep. 26, 2017
-
Patent Title: Compositions and methods of engineered crispr-cas9 systems using split-nexus cas9-associated polynucleotides Aug. 29, 2017
-
Patent Title: Methods of using engineered nucleic-acid targeting nucleic acids Aug. 29, 2017
-
Patent Title: Compositions and methods of nucleic acid-targeting nucleic acids Aug. 08, 2017
-
Patent Title: Engineered nucleic-acid targeting nucleic acids Jun. 13, 2017
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Recent insights relating to CRBU
Recent picks made for CRBU stock on CNBC
ETFs with the largest estimated holdings in CRBU
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $CRBU stock a Buy, Sell, or Hold?
- What is the price target for $CRBU stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $CRBU stock?
- Who owns the most shares of $CRBU stock?
- What funds own $CRBU stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view CRBU Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.